Medacta (SIX:MOVE) published its full fiscal 2025 financial results on Thursday, reporting adjusted EBITDA and margin outcomes that outperformed market expectations even as foreign exchange movements continued to pressure gross profit.
The Switzerland-based orthopedic and neurosurgical device manufacturer recorded an adjusted EBITDA of 11 million for the year, which was 1% ahead of consensus estimates pegged at a 27.5% adjusted EBITDA margin. On a reported basis that includes the Parcus acquisition, EBITDA came in at 201.5 million. Management said adjusted EBITDA margin for the full year was 27.9%, and rose to 29% when calculated in constant currencies.
Medacta also highlighted that adjusted EBITDA in the second half of the fiscal year exceeded expectations by roughly 3%, noting that this performance came despite foreign exchange headwinds similar to those seen in the prior fiscal year. The company attributed the outperformance in part to cost savings in sales and marketing.
Cash generation showed clear improvement. Operating cash flow increased by 42.5% year-over-year to 152.7 million. Free cash flow advanced to 15.7 million from 8.3 million in the prior year, though free cash flow remained constrained by significant capital investment totaling 137.0 million.
Approximately 80% of that capital expenditure was directed to growth initiatives. The company disclosed 78.2 million of spending on surgical instruments and the balance to expanding production facilities, signaling continued emphasis on capacity and product investments.
For fiscal 2026, Medacta issued revenue guidance calling for 10% to 14% growth on a constant currency basis. The firm also raised its midterm growth target to a 12% to 15% range, up from the prior 10% to 14%. The fiscal 2026 outlook includes an expected expansion of the adjusted EBITDA margin by 50 basis points from the roughly 27.9% starting point.
Alongside the results, the company announced a dividend that was 12% ahead of analyst expectations. Medacta had pre-announced top-line figures in February and emphasized profitability and cash flow heading into the full-year results disclosure. Management scheduled a conference call to discuss the results at 15:00 CET.
Medacta develops, manufactures and distributes orthopedic and neurosurgical products across hip, knee, shoulder and spine indications. The Siccardi family maintains a 70% ownership stake in the business.
Context and operational focus
The firm s results reflect a dual dynamic: margin recovery driven by cost reductions in commercial functions alongside continued currency-related pressure on gross profit. The heavy level of capital expenditure - primarily on surgical instruments and production capacity - constrained free cash flow this year but was presented as investment in growth capacity.
Investors will likely weigh the margin gains and stronger operating cash flow against ongoing capital intensity and external currency effects as they assess the company s ability to convert higher revenue into sustained free cash flow.